[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"peptic-ulcer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:peptic-ulcer":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,44,75,104,131,154,177],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100635901","fexuclue-for-prevention-of-nsaids-induced-peptic-ulcer-in-real-world-practice-100635901",false,"NCT07558707","Fexuclue for Prevention of NSAIDs-Induced Peptic Ulcer in Real-World Practice","A Prospective, Multi-Center, Observational Study to Evaluate the Efficacy and Safety of Fexuclue Tablet 20 mg in Patients Requiring NSAIDs-Induced Peptic Ulcer Prevention","Inclusion Criteria:\n\n* Adults aged ≥19 years\n* Patients requiring NSAIDs therapy\n* Patients requiring prevention of NSAIDs-induced peptic ulcer\n* Patients prescribed Fexuclue Tablet 20 mg\n* Patients who provide written informed consent\n\nExclusion Criteria:\n\n* Hypersensitivity to Fexuclue or its components\n* Severe hepatic impairment\n* Pregnant or breastfeeding women\n* Patients considered inappropriate by investigator","ALL","19 Years",{"count":19,"type":20},7000,"ESTIMATED","OBSERVATIONAL","This study is a prospective, multi-center, observational study to evaluate the efficacy and safety of Fexuclue Tablet 20 mg in patients requiring prevention of NSAIDs-induced peptic ulcer in real-world clinical practice in Korea.\n\nPatients receiving NSAIDs and requiring gastroprotective therapy will be enrolled and followed prospectively. The study will assess patient-reported outcomes (PROs) related to gastrointestinal symptoms, as well as safety outcomes.",[24,25],"Peptic Ulcer","NSAID-Induced Peptic Ulcer",[27,28,29,30,31],"NSAIDs","Fexuprazan","PRO","Real-World","Peptic Ulcer Prevention","NOT_YET_RECRUITING","2026-04-27",{"date":35,"type":36},"2026-04-30","ACTUAL",{"date":35,"type":20},{"date":39,"type":20},"2027-12-31",{"name":41,"class":42},"Daewoong Pharmaceutical Co. LTD.","INDUSTRY",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":54,"conditions":55,"keywords":60,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":4},"100628196","predicting-peptic-complications-using-h-pylori-serology-and-gastric-ultrasound-100628196","NCT07458490","Predicting Peptic Complications Using H. Pylori Serology and Gastric Ultrasound","H. Pylori Serology and Gastric Ultrasound Findings in Predicting Peptic Complications","Inclusion Criteria:\n\n* Adult patients (age ≥18 years) presenting with dyspeptic symptoms (epigastric pain, nausea, vomiting, heartburn).\n* Patients with suspected or confirmed peptic ulcer disease.\n* Patients presenting with acute complications (hematemesis, melena, acute - abdominal pain suggestive of perforation).\n* Patients with history of peptic ulcer disease requiring surveillance.\n* Patients who provide informed consent.\n\nExclusion Criteria:\n\n* Previous gastric surgery (gastrectomy, vagotomy).\n* Active malignancy (gastric cancer, lymphoma).\n* Previous H. pylori eradication therapy within 4 weeks.\n* Current use of proton pump inhibitors (PPIs) within 2 weeks (may affect antibody levels and ultrasound findings).\n* Severe coagulopathy or bleeding disorders (INR \\>2.0).\n* Pregnancy.\n* Poor quality ultrasound images due to excessive bowel gas or obesity.\n* Hemodynamically unstable patients requiring immediate intervention.\n* Refusal to participate in the study.","18 Years",{"count":53,"type":20},230,"This observational study aims to evaluate whether combining a simple blood test (H. pylori serology) with a non-invasive abdominal ultrasound can accurately predict severe complications in patients with peptic ulcer disease (PUD). Peptic ulcer complications, such as stomach bleeding or perforation, are serious and typically require an invasive procedure called an upper endoscopy for diagnosis and treatment.\n\nResearchers want to find out if these two non-invasive tests can be used together to create a reliable risk-scoring system. This system would help doctors quickly identify which patients are at a high risk for complications and need an urgent endoscopy, compared to those who are at a lower risk and can be safely monitored without the invasive procedure.\n\nThe study will include adult patients presenting with stomach symptoms (like pain, nausea, or heartburn), as well as those with suspected or confirmed peptic ulcer disease. Participants will provide a blood sample to check for H. pylori antibodies and undergo a standard, painless abdominal ultrasound to examine the thickness of their stomach wall. An upper gastrointestinal endoscopy will be performed if it is clinically necessary as part of the patient's standard medical care.",[56,57,58,24,59],"Peptic Ulcer Disease","HELICOBACTER PYLORI INFECTIONS","Helicobacter Pylori Infection","Dyspepsia",[61,62,63,56,58,64,59],"H. pylori serology","gastric ultrasound","peptic complications","Peptic Ulcer Complications","2026-03-04",{"date":67,"type":36},"2026-03-09",{"date":69,"type":20},"2026-04",{"date":71,"type":20},"2027-05",{"name":73,"class":74},"Assiut University","OTHER",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":86,"studyType":21,"phases":4,"briefSummary":87,"conditions":88,"keywords":92,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":103},"100617214","the-effect-of-vascular-imaging-devices-on-success-rates-of-peripheral-vascular-access-in-pediatric-patients-100617214","NCT07315711","The Effect of Vascular Imaging Devices on Success Rates of Peripheral Vascular Access in Pediatric Patients","The Effect of Vascular Imaging Devices on the Success Rate of Peripheral Vascular Access in Pediatric Patients Undergoing Day-Case and Non-Operating Room Anesthesia Procedures","Inclusion Criteria:\n\n* Pediatric patients aged 0-18 years scheduled for day-case surgery or non-operating room anesthesia (NORA)\n\nPatients requiring peripheral vascular access (those with a need for intravenous access)\n\nPatients whose parent or legal guardian can provide written informed consent\n\nPatients suitable for vascular access using a vascular imaging device\n\nExclusion Criteria:\n\nPatients requiring emergency surgery or urgent intervention\n\nPatients whose parent or legal guardian cannot provide informed consent\n\nPatients with local extremity problems such as infection, edema, or wound that prevent peripheral vascular access placement\n\n\\-","0 Days","18 Days",{"count":85,"type":20},500,"1 Day","The study was designed as a prospective, observational study. Pediatric patients under 18 years of age scheduled for peripheral vascular access placement during day-case surgery or non-operating room anesthesia (NORA) will be included. The primary outcomes include time to successful vascular access, number of attempts, and number of interventions (defined as each new skin entry of the needle). These outcomes will be compared between two groups: those who receive vascular access with the aid of a vascular imaging device and those in whom such a device is not used.",[89,24,90,91],"Peripheral Vascular Access in Pediatric Patients","Cataract","Crohn's Disease",[93],"non-operating room anesthesia (NORA), peripheral vascular access, pediatric patienent","2025-12-23",{"date":96,"type":36},"2026-01-02",{"date":98,"type":20},"2025-12-01",{"date":100,"type":20},"2027-12-01",{"name":102,"class":74},"Sibel Seçkin Pehlivan",6,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":114,"phases":115,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":43},"100603657","phase-4-saccharomyces-boulardii-combined-with-bismuth-quadruple-therapy-for-helicobacter-pylori-rescue-treatment-100603657","NCT07139366","Saccharomyces Boulardii Combined With Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Treatment","Efficacy and Safety of Saccharomyces Boulardii Combined With Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Treatment: A Prospective, Multicenter, Randomized Controlled Trial","Inclusion Criteria:\n\n* Age between 18\\~75, both gender.\n* Patients who had failed H.pylori eradication therapies .\n* Women are eligible if they are not pregnant or nursing, and if they are of childbearing potential they are required to use medically acceptable contraception for the duration of the study and 30 days thereafter.\n\nExclusion Criteria:\n\n* Patients who have previously used tetracycline and furazolidone antibiotics to eradicate infection with H. pylori.\n* Contraindications to study drugs.\n* Substantial organ impairment, severe or unstable cardiopulmonary or endocrine disease.\n* Constant use of anti-ulcer drugs ( including taking proton-pump.inhibitors(PPI) within 2 weeks before the \\[13C\\] urea breath test), antibiotics or bismuth complexes (more than 3 times \u002F1 month before screening).\n* Pregnant or lactating women.\n* Underwent upper gastrointestinal Surgery.\n* Dysphagia.\n* Evidence of bleeding or iron efficiency anemia.\n* A history of malignancy.\n* Drug or alcohol abuse history in the past 1 year.\n* Systemic use of corticosteroids, non steroidal anti-inflammatory drugs, anticoagulants, platelet aggregation inhibitors (except the use of aspirin for less than 100 mg\u002Fd).\n* Mental disorder.\n* Enrolled in other clinical trials in the past 3 months.\n* Refuse to sign informed consent.","75 Years",{"count":113,"type":20},1248,"INTERVENTIONAL",[116],"PHASE4","This study aims at evaluating efficacy and safety of Saccharomyces boulardii combined with bismuth-containing quadruple Therapy versus bismuth-containing quadruple Therapy(bismuth#esomeprazole#tetracycline and furazolidone) in H. pylori rescue therapy. It is hypothesized that Saccharomyces boulardii combined with bismuth-containing quadruple Therapy is superior to bismuth-containing quadruple Therapy. Patients with confirmed failure of H. pylori eradication will be randomized to one of the treatments described above. At week 6 follow-up visits, a urea breath test#rapid urease test or helicobacter pylori stool antigen test will be performed to confirm eradication.",[119,59,58,120,24],"Gastritis","Gastric Cancer","RECRUITING","2025-11-30",{"date":124,"type":36},"2025-12-02",{"date":126,"type":36},"2025-10-28",{"date":128,"type":20},"2026-09",{"name":130,"class":74},"Yongquan Shi",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":16,"minAge":138,"maxAge":139,"enrollmentInfo":140,"targetDuration":4,"studyType":114,"phases":142,"briefSummary":144,"conditions":145,"keywords":4,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":43},"100612932","treatment-efficacy-of-regimens-with-and-without-bismuth-in-children-with-helicobacter-pylori-associated-peptic-ulcer-disease-100612932","NCT07260006","Treatment Efficacy of Regimens With and Without Bismuth in Children With Helicobacter Pylori-Associated Peptic Ulcer Disease","A Study on the Treatment Efficacy of Regimens With and Without Bismuth in Children With Helicobacter Pylori-Associated Peptic Ulcer Disease","Inclusion Criteria:\n\n* Diagnosed with gastritis or peptic ulcer disease by upper gastrointestinal endoscopy or histopathology.\n* Meets diagnostic criteria for Helicobacter pylori infection.\n* Parent or legal guardian provides consent for the child to participate in the study.\n\nExclusion Criteria:\n\n* Allergic to any of the medications in the treatment regimen.\n* Use of antibiotics or bismuth within the past 4 weeks, or use of antacids, H2-receptor antagonists, or proton pump inhibitors within the past 2 weeks.\n* Failure to return for follow-up visits after treatment.","5 Years","15 Years",{"count":141,"type":20},80,[143],"NA","The goal of this clinical trial is to learn if including bismuth in the treatment helps heal stomach and duodenal ulcers caused by Helicobacter pylori (H. pylori) in children.\n\nThe main questions it aims to answer are:\n\n* Does a treatment plan with bismuth work better than a plan without bismuth to clear the infection?\n* Is the bismuth plan more cost-effective while still safe and effective?\n\nResearchers will compare two treatment groups to see which works better. Participants will:\n\n* Take one of the two assigned treatment plans (with or without bismuth) for the standard treatment duration\n* Visit the clinic for checkups and tests to confirm infection clearance and monitor side effects\n* Keep a diary of symptoms, medication use, and any side effects",[58,24],"2025-11-21",{"date":124,"type":36},{"date":149,"type":36},"2024-10-01",{"date":151,"type":20},"2026-05-30",{"name":153,"class":74},"Can Tho University of Medicine and Pharmacy",{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":114,"phases":163,"briefSummary":165,"conditions":166,"keywords":4,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":176},"100537980","phase-3-study-to-evaluate-the-efficacy-and-safety-of-ilaprazole-10-mg-in-prevention-nsaids-associated-peptic-ulcer-100537980","NCT06284876","Study to Evaluate the Efficacy and Safety of Ilaprazole 10 mg in Prevention NSAIDs Associated Peptic Ulcer","A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Ilaprazole 10 mg in Prevention NSAIDs Associated Peptic Ulcer","Inclusion Criteria:\n\n1. Adult males and females aged 19 years or older on the day of informed consent\n2. Subjects requiring continuous treatment or receiving treatment with NSAIDs\n3. Subjects with at least one of following peptic ulcer risk factors at the time of Screening\n4. Subjects who have provided voluntary informed consent for the study participation after the study is explained\n\nExclusion Criteria:\n\n1. Subjects with Gastroesophageal varices, Esophageal stricture or ulcerous stenosis, Gastrointestinal bleeding or perforation, Esophageal dysplasia and else based on the screening EGD results.\n2. Subjects with inflammatory bowel diseases, pancreatitis, pyloric obstruction, and primary esophageal motility disorder\n3. Subjects with confirmed history of malignancy within 5 years prior to Screening\n4. Positive human immunodeficiency virus (HIV) antigen\u002Fantibody at Screening",{"count":162,"type":20},416,[164],"PHASE3","To demonstrate the non-inferiority of Ilaprazole 10 mg to the active control in prevention of NSAIDs-associated peptic ulcer, as assessed by the proportion of subjects with peptic ulcer by Week 24",[24],"2025-05-25",{"date":169,"type":36},"2025-05-30",{"date":171,"type":36},"2024-07-23",{"date":173,"type":20},"2027-02-28",{"name":175,"class":42},"Il-Yang Pharm. Co., Ltd.",2,{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":114,"phases":186,"briefSummary":187,"conditions":188,"keywords":4,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":43},"100549861","phase-3-study-to-evaluate-the-efficacy-and-safety-of-jp-1366-in-the-prevention-of-nsaids-induced-peptic-ulcers-100549861","NCT06439563","Study to Evaluate the Efficacy and Safety of JP-1366 in the Prevention of NSAIDs-Induced Peptic Ulcers","A Multicenter, Parallel, Double-blind, Randomized, Active-controlled, Non-inferiority, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of JP-1366 Treatment in the Prevention of (NSAIDs)-Induced Peptic Ulcers","Inclusion Criteria:\n\n1. Adult male\u002Ffemale aged 19 years or older as of the date of obtaining consent\n2. Those who are diagnosed with musculoskeletal diseases such as rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, or other diseases at the time of screening and require continuous administration of NSAIDs for 24 weeks or more\n3. Those with one or more of the following risk factors for ulcer development at the time of screening\n4. Subjects who fully understand this study and voluntarily signed the informed consent form.\n\nExclusion Criteria:\n\n1. Those who cannot undergo upper gastrointestinal endoscopy\n2. At the time of screening, those who were confirmed to have active stage ulcers (A1, A2) or healing stage ulcers (H1, H2) in the stomach or duodenum according to the Sakita-Miwa Classification\\*\n3. Those with a confirmed history of malignant tumor within 5 years\n4. Those with a confirmed history of signal symptoms suggestive of malignant disease of the gastrointestinal tract\n5. Those who need to continuously take corticosteroids, antiplatelet agents, and anticoagulants during this study (however, the following cases are permitted):\n6. Pregnant and lactating women or those with a positive pregnancy test result at screening\n7. Those who participated in another study and were administered investigational products or had medical devices applied at least once within 4 weeks from the screening visit(Visit 0)",{"count":185,"type":20},364,[164],"The sutdy aims to to demonstrate the non-inferiority of JP-1366 10 mg compared to Lanston Capsule 15 mg in preventing NSAIDs-induced peptic ulcers and to compare\u002Fevaluate the efficacy and safety of JP-1366 10 mg.",[24],"2024-10-30",{"date":191,"type":36},"2024-11-01",{"date":193,"type":36},"2024-10-22",{"date":195,"type":20},"2027-12",{"name":197,"class":42},"Onconic Therapeutics Inc."]